Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akçetin L, Kölblinger P, Hoellwerth M, Meissner M, Mengi G, Braun AD, Mengoni M, Dummer R, Mangana J, Sindrilaru MA, Radmann D, Hafner C, Freund J, Rappersberger K, Weihsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler JM, Höller C, Eigentler T, Amaral T, Peitsch WK, Hillen U, Harth W, Ziller F, Schatton K, Gambichler T, Susok L, Maul LV, Läubli H, Debus D, Weishaupt C, Börger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen VA, Wanner M, Gutzmer R, Terheyden P, Kähler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune KM, Thoms KM, Heinzerling L, Heppt MV, Tratzmiller S, Hoetzenecker W, Öllinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posch C. Schumann K, et al. Among authors: ressler jm. J Eur Acad Dermatol Venereol. 2023 May;37(5):894-906. doi: 10.1111/jdv.18779. Epub 2022 Dec 12. J Eur Acad Dermatol Venereol. 2023. PMID: 36433688
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Ressler JM, et al. J Immunother Cancer. 2021 Feb;9(2):e001701. doi: 10.1136/jitc-2020-001701. J Immunother Cancer. 2021. PMID: 33608376 Free PMC article.
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E, Nguyen VA, Koelblinger P, Wolf I, Kehrer H, Saxinger W, Ressler JM, Weinlich G, Meyersburg D, Hafner C, Jecel-Grill E, Kofler J, Lange-Asschenfeldt B, Weihsengruber F, Rappersberger K, Svastics N, Gasser K, Seeber A, Kratochvill F, Nagler S, Mraz B, Hoeller C. Richtig E, et al. Among authors: ressler jm. Melanoma Res. 2024 Apr 1;34(2):142-151. doi: 10.1097/CMR.0000000000000948. Epub 2023 Dec 13. Melanoma Res. 2024. PMID: 38092013 Free PMC article.
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM, McKeown J, Dimitriou F, Jacques SK, Zimmer L, Allayous C, Yeoh HL, Haydon A, Ressler JM, Galea C, Woodford R, Kahler K, Hauschild A, Festino L, Hoeller C, Schwarze JK, Neyns B, Wicky A, Michielin O, Placzke J, Rutkowski P, Johnson DB, Lebbe C, Dummer R, Ascierto PA, Lo S, Long GV, Carlino MS, Menzies AM. Taylor AM, et al. Among authors: ressler jm. Eur J Cancer. 2024 Mar;199:113561. doi: 10.1016/j.ejca.2024.113561. Epub 2024 Jan 20. Eur J Cancer. 2024. PMID: 38278009
Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.
L'Orphelin JM, Cassecuel J, Kandolf L, Harwood CA, Tookey P, Junejo MH, Hogan S, Lebbé C, Appalla Z, Kränke TM, Pellacani G, Cerasuolo D, Dujovic B, Del Marmol V, Forschner A, Garbe C, Bataille V, Ressler JM, Sollena P, Dompmartin A, Peris K, Dreno B; And European Association of Dermato-Oncology. L'Orphelin JM, et al. Among authors: ressler jm. J Eur Acad Dermatol Venereol. 2023 Apr 12. doi: 10.1111/jdv.19112. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 37042810
Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial.
Menzies SW, Sinz C, Menzies M, Lo SN, Yolland W, Lingohr J, Razmara M, Tschandl P, Guitera P, Scolyer RA, Boltz F, Borik-Heil L, Herbert Chan H, Chromy D, Coker DJ, Collgros H, Eghtedari M, Corral Forteza M, Forward E, Gallo B, Geisler S, Gibson M, Hampel A, Ho G, Junez L, Kienzl P, Martin A, Moloney FJ, Regio Pereira A, Ressler JM, Richter S, Silic K, Silly T, Skoll M, Tittes J, Weber P, Weninger W, Weiss D, Woo-Sampson P, Zilberg C, Kittler H. Menzies SW, et al. Among authors: ressler jm. Lancet Digit Health. 2023 Oct;5(10):e679-e691. doi: 10.1016/S2589-7500(23)00130-9. Lancet Digit Health. 2023. PMID: 37775188 Free article. Clinical Trial.
11 results